# Antibody responses to HCV vaccine antigens in infection and vaccination

> **NIH NIH U19** · SCRIPPS RESEARCH INSTITUTE, THE · 2020 · $453,759

## Abstract

Project 1 Summary
HCV infects nearly 3% of the world population and is a leading cause of liver cirrhosis and
cancer. A vaccine that can stop virus transmission will be a highly valuable tool for the public
health system. However, HCV is antigenically variable and an effective vaccine must target
conserved immune epitopes on the virus. An important goal in HCV vaccine is to develop
antigens that will elicit broadly neutralizing antibodies (bNAbs). The proposed project aims to
discover the epitopes targeted by bNAbs during vaccination and natural infection, and the
evolutionary pathways of bnAbs. The knowledge learned from the human studies will be applied
to studying the antibody responses in mice, guinea pigs and non-human primates immunized
with candidate HCV vaccine antigens. The research will help uncover the pros and cons of each
animal model as a preclinical model for efficacy study of future HCV vaccine candidates. This
project will contribute to the knowledge and tools for the development of a broadly effective HCV
vaccine.

## Key facts

- **NIH application ID:** 9903197
- **Project number:** 5U19AI123861-05
- **Recipient organization:** SCRIPPS RESEARCH INSTITUTE, THE
- **Principal Investigator:** Mansun Law
- **Activity code:** U19 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2020
- **Award amount:** $453,759
- **Award type:** 5
- **Project period:** — → —

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/9903197

## Citation

> US National Institutes of Health, RePORTER application 9903197, Antibody responses to HCV vaccine antigens in infection and vaccination (5U19AI123861-05). Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/grant/nih/9903197. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*